专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006076595A8 HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH 审中-公开
标题翻译：卤代取代的氨基酸，其组合物及其治疗方法
公开(公告)号：WO2006076595A8
公开(公告)日：2006-10-05
申请号：PCT/US2006001275
申请日：2006-01-13
申请人： SIGNAL PHARM LLC , ALBERS RONALD , AYALA LETICIA , CLAREEN STEVEN S , DELGADO MEDEROS MARIA M , HILGRAF ROBERT , HEDGE SAYEE , HUGHES KEVIN , KOIS ADAM , PLANTEVIN-KRENITSKY VERONIQUE , MCCARRICK MEG , NADOLNY LISA , PALANKI MOORTHY , SAHASRABUDHE KIRAN , SAPIENZA JOHN , SATOH YOSHITAKA , SLOSS MARIAN , SUDBECK ELISE , WRIGHT JONATHAN
发明人： ALBERS RONALD , AYALA LETICIA , CLAREEN STEVEN S , DELGADO MEDEROS MARIA M , HILGRAF ROBERT , HEDGE SAYEE , HUGHES KEVIN , KOIS ADAM , PLANTEVIN-KRENITSKY VERONIQUE , MCCARRICK MEG , NADOLNY LISA , PALANKI MOORTHY , SAHASRABUDHE KIRAN , SAPIENZA JOHN , SATOH YOSHITAKA , SLOSS MARIAN , SUDBECK ELISE , WRIGHT JONATHAN
IPC分类号： C07D473/00 , A61K31/52 , A61P3/00 , A61P9/00 , C07D473/32
CPC分类号： C07D473/00 , A61K31/52 , C07D473/32
摘要： Provided herein are Aminopurine Compounds having the following structure: (I) wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
摘要翻译：本文提供的是具有以下结构的氨基嘌呤化合物：其中R 1，R 2和R 3如本文所定义，（I）其中R 1，R 2和R 3如本文所定义，其包含有效量的氨基嘌呤化合物以及用于治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症，炎性病症，黄斑变性，局部缺血 - 再灌注损伤，疼痛和相关综合征，疾病相关性消瘦，石棉相关病症，肺性高血压或通过抑制JNK途径可治疗或可预防的病症，所述方法包括向有需要的患者施用有效量的氨基嘌呤化合物。

2. 发明申请

WO2008036308A2 AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH 审中-公开
标题翻译：氨基取代的杂环化合物，其组合物及其处理方法
公开(公告)号：WO2008036308A2
公开(公告)日：2008-03-27
申请号：PCT/US2007020286
申请日：2007-09-18
申请人： SIGNAL PHARM LLC , D SIDOCKY NEIL R , HARRIS ROY L III , HEGDE SAYEE G , HILGRAF ROBERT , MCCARRICK MARGARET A , MCKIE JEFFREY A , MORTENSEN DEBORAH S , NADOLNY LISA , PERIN-NINKOVIC SOPHIE M , SAPIENZA JOHN J , WRIGHT JONATHAN L
发明人： D SIDOCKY NEIL R , HARRIS ROY L III , HEGDE SAYEE G , HILGRAF ROBERT , MCCARRICK MARGARET A , MCKIE JEFFREY A , MORTENSEN DEBORAH S , NADOLNY LISA , PERIN-NINKOVIC SOPHIE M , SAPIENZA JOHN J , WRIGHT JONATHAN L
CPC分类号： C07D417/04 , C07D285/135 , C07D403/04 , C07D417/14
摘要： Provided herein are Heterocyclic Compounds having the following structure: Formula (I) wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.
摘要翻译：本文提供具有以下结构的杂环化合物：其中R 1，R 2，X，Y和Z如本文所定义的式（I），包含有效量的组合物的杂环化合物以及用于治疗或预防癌症，炎性病症，免疫学条件，代谢条件和通过抑制激酶途径可治疗或可预防的病症的方法，包括向有需要的患者施用有效量的杂环化合物。

3. 发明专利

AU2011202888A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith 未知
公开(公告)号：AU2011202888A1
公开(公告)日：2011-07-07
申请号：AU2011202888
申请日：2011-06-16
申请人： SIGNAL PHARM LLC , PHARMACOPEIA LLC
发明人： KOIS ADAM , SATOH YOSHITAKA , SUDBECK ELISE , HENDERSON IAN , SAPIENZA JOHN , WRIGHT JONATHAN , HUGHES KEVIN , SAHASRABUDHE KIRAN , AYALA LETICIA , NADOLNY LISA , DELGADO MEDEROS MARIA M , SLOSS MARIAN , MCCARRICK MEG , PALANKI MOORTHY , HILGRAF ROBERT , ALBERS RONALD , HEDGE SAYEE , CLAREEN STEVEN S , PLANTEVIN-KRENITSKY VERONIQUE , COLE ANDREW G
IPC分类号： C07D473/00 , A61K31/52 , A61P3/00 , A61P9/00 , C07D473/32
摘要： Provided herein are Aminopurine Compounds having the following structure: (I) wherein R', R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing Type I diabetes, Type II diabetes, esophagitis, hepatitis, pancreatitis or nephritis, cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos relate condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

4. 发明专利

CR20110132A AMINOTRIAZOLOPIRIDINAS Y SU USO COMO INHIBIDORES DE CINASA 未知
公开(公告)号：CR20110132A
公开(公告)日：2011-06-20
申请号：CR20110132
申请日：2011-03-11
申请人： SIGNAL PHARM LLC
发明人： BAHMANYAR SOGOLE , BATES R J , BLEASE KATE , CALABRESE ANDREW ANTONY , DANIEL THOMAS ORAN , DELGADO MERCEDES , ELSNER JAN , ERDMAN PAUL , FAHR BRUCE , FERGUSON GREGORY , LEE BRANDEN , NADOLNY LISA , PACKARD GARRICK , PAPA PATRICK , PLANTEVIN-KRENITSKY VERONIQUE , RIGGS JENNIFER , ROHANE PATRICIA , SANKAR SABITA , SAPIENZA JOHN , SATOH YOSHITAKA , SLOAN VICTOR , STEVENS RANDALL , TEHRANI LIDA , TIKHE JAYASHREE , TORRES EDUARDO , WALLACE ANDREW , WHITEFIELD BRANDON WADE , ZHAO JINGJING
IPC分类号： C07D471/04
摘要： Se proporcionan en la presente Compuestos de Heteroarilo de la fórmula (I): donde R1 y R2 son como se definen en la presente, composiciones que comprenden una cantidad efectiva de un Compuesto de Heteroarilo y métodos para tratar o prevenir condiciones inflamatorias o cáncer, y condiciones tratables o prevenibles por la inhibición de una cinasa o ruta de cinasa que comprende administrar una cantidad efectiva de un Compuesto de Heteroarilo a un sujeto en necesidad del mismo.

6. 发明专利

CA2595182A1 HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, ANDMETHODS OF TREATMENT THEREWITH 未知
公开(公告)号：CA2595182A1
公开(公告)日：2006-07-20
申请号：CA2595182
申请日：2006-01-13
申请人： PHARMACOPEIA DRUG DISCOVERY , SIGNAL PHARM LLC
发明人： ALBERS RONALD , HEDGE SAYEE , SLOSS MARIAN , SUDBECK ELISE , SATOH YOSHITAKA , WRIGHT JONATHAN , SAPIENZA JOHN , HUGHES KEVIN , DELGADO MEDEROS MARIA M , NADOLNY LISA , HILGRAF ROBERT , KOIS ADAM , MCCARRICK MEG , PALANKI MOORTHY , PLANTEVIN-KRENITSKY VERONIQUE , AYALA LETICIA , SAHASRABUDHE KIRAN , CLAREEN STEVEN S
IPC分类号： C07D473/00 , A61K31/52 , A61P3/00 , A61P9/00 , C07D473/32
摘要： Provided herein are Aminopurine Compounds, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

7. 发明专利

AU2006204792A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith 未知
公开(公告)号：AU2006204792A1
公开(公告)日：2006-07-20
申请号：AU2006204792
申请日：2006-01-13
申请人： PHARMACOPEIA DRUG DISCOVERY , SIGNAL PHARM LLC
发明人： HENDERSON IAN , NADOLNY LISA , AYALA LETICIA , SAPIENZA JOHN , ALBERS RONALD , MCCARRICK MEG , MEDEROS MARIA M DELGADO , HEDGE SAYEE , HUGHES KEVIN , CLAREEN STEVEN S , SUDBECK ELISE , SATOH YOSHITAKA , SLOSS MARIAN , SAHASRABUDHE KIRAN , KOIS ADAM , HILGRAF ROBERT , COLE ANDREW G , PALANKI MOORTHY , PLANTEVIN-KRENITSKY VERONIQUE , WRIGHT JONATHAN
IPC分类号： C07D473/00 , A61K31/52 , A61P3/00 , A61P9/00 , C07D473/32
摘要： Provided herein are Aminopurine Compounds, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

9. 发明专利

CY1109306T1 ΥΠΟΚΑΤΑΣΤΑΘΕΙΣΕΣ ΜΕ ΑΛΟΓΟΝΟΑΡΥΛΙΟ ΑΜΙΝΟΠΟΥΡΙΝΕΣ, ΣΥΝΘΕΣΕΙΣ ΤΟΥΣ ΚΑΙ ΜΕΘΟΔΟΙ ΑΓΩΓΗΣ ΜΕ ΑΥΤΕΣ 未知
公开(公告)号：CY1109306T1
公开(公告)日：2014-07-02
申请号：CY091100859
申请日：2009-08-12
申请人： SIGNAL PHARM LLC
发明人： ALBERS RONALD , AYALA LETICIA , CLAREEN STEVEN S , DELGADO MEDEROS MARIA M , HILGRAF ROBERT , HEDGE SAYEE , HUGHES KEVIN , KOIS ADAM , PLANTEVIN-KRENITSKY VERONIQUE , MCCARRICK MEG , NADOLNY LISA , PALANKI MOORTHY , SAHASRABUDHE KIRAN , SAPIENZA JOHN , SATOH YOSHITAKA , SLOSS MARIAN , SUDBECK ELISE , WRIGHT JONATHAN , COLE ANDREW G , HENDERSON IAN
IPC分类号： C07D473/00 , A61K31/52 , A61P3/00 , A61P9/00 , C07D473/32
摘要： Παρέχονταιεδώπαράγωγααμινοπουρίνηςέχοντατηνακόλουθηδομή: (I) όπουτα R1, R2 και R3 είναιόπωςορίζονταιεδώ, συνθέσειςπεριλαμβάνουσεςμίααποτελεσματικήποσότηταενόςπαραγώγουαμινοπουρίνηςκαιμέθοδοιγιατηναγωγήή τηνπρόληψητουκαρκίνου, μίαςκαρδιαγγειακήςνόσου, μίαςνεφρικήςνόσου, μίαςαυτοάνοσηςκαταστάσεως, μίαςφλεγμονώδουςκαταστάσεως, τουεκφυλισμούτηςωχράςκηλίδας, τηςβλάβηςισχαιμίας-επαναιματώσεως, τουάλγουςκαιπαρόμοιωνσυνδρόμων, τηςσχετιζόμενηςμεασθένειαεξαντλήσεως, μίαςκαταστάσεωςσχετιζόμενηςμετοναμίαντο, τηςπνευμονικήςυπερτάσεωςή μίαςκαταστάσεωςη οποίαμπορείνααντιμετωπισθείή ναπροληφθείδι' αναστολήςτηςοδούτης JNK, περιλαμβάνουσεςτηχορήγησημίαςαποτελεσματικήςποσότηταςενόςπαραγώγουαμινοπουρίνηςσεένανασθενήο οποίοςτηνέχειανάγκη.

10. 发明专利

NZ591551A AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS 未知
公开(公告)号：NZ591551A
公开(公告)日：2011-10-28
申请号：NZ59155109
申请日：2009-09-08
申请人： SIGNAL PHARM LLC
发明人： BAHMANYAR SOGOLE , BATES R J , BLEASE KATE , CALABRESE ANDREW ANTONY , DANIEL THOMAS ORAN , DELGADO MERCEDES , ELSNER JAN , ERDMAN PAUL , FAHR BRUCE , FERGUSON GREGORY , LEE BRANDEN , NADOLNY LISA , PACKARD GARRICK , PAPA PATRICK , PLANTEVIN-KRENITSKY VERONIQUE , RIGGS JENNIFER , ROHANE PATRICIA , SANKAR SABITA , SAPIENZA JOHN , SATOH YOSHITAKA , SLOAN VICTOR , STEVENS RANDALL , TEHRANI LIDA , TIKHE JAYASHREE , TORRES EDUARDO , WALLACE ANDREW , WHITEFIELD BRANDON WADE , ZHAO JINGJING
IPC分类号： A61P35/00 , A61K31/437 , A61P5/00 , A61P9/00 , A61P19/00 , A61P25/00 , A61P29/00 , C07D471/04
摘要： Disclosed is a compound of formula (1) e.g. (R)-3 ,3-dimethyl-6-(5-(methyl(tetrahydrofuran-3-yl)amino )-[1,2,4]triazolo[1 ,5-a ]pyridin-2-ylamino)indolin-2-one or a pharmaceutically acceptable salt, tautomer, stereoisomer, or solvate thereof, wherein: R' is an aryl, or a heterocyclyl; R2 is an alkyl, a cycloalkyl, a heterocyclylalkyl, an aralkyl, -NR3R4, -OR3, -C(=O)R5, -C(=O)NR3R4 -NHC(=O)R3, -(CH2)CR6(OR3)R4, or a heterocyclyl selected from azetidinyl, pyrrolidyl, piperidyl, morpholinyl, piperazin-2-onyl,1,2,3,6-tetrahydropyridyl, isoxazolyl, imidazolyl, indazolyl, benzimidazolyl, 1-H-benzo[d][1 ,2,3]triazolyl, benzisoxazolyl, benzo[ d]oxazolyl, isoindolin-lonyl,1H-imidazo[4,5-b ]pyridyl, isoquinolinyl, or quinolyl; or R2 is pyridyl; R3 and R4 are at each occurrence independently -H, an alkyl, anaryl, a heteroaryl, a cycloalkyl, a substituted or a heterocyclyl, an aralkyl, or a heterocyclylalkyl; R5 is alkyl, an aryl, a heteroaryl, a cycloalkyl, a heterocyclyl, an aralkyl, or a heterocyclylalkyl; and R6 is -H, or an alkyl, or together with R4 and the atoms to which they are attached form a heterocyclyl for the treatment of cancer where the cancer is of the head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, brea$t, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors or blood-borne tumors and Behcet's syndrome, a non-allergy mast cell disease, ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, multiple sclerosis, lupus, inflammatory bowel disease, ulcerative colitis, Crohn's disease, myasthenia gravis, Grave's disease, transplant rejection, humoral transplant rejection, non-humoral transplant rejection, cellular transplant rejection, immune thrombocytopenic purpura, idiopathic thrombocytopenic purpura, diabetes, immunological response to bacterial, parasitic, helminth infestation or viral infection, eczema, dermatitis, graft versus host disease, Goodpasture's disease, hemolytic disease of the newborn, autoimmune hemolytic anemia, anti-phospholipid syndrome, ANCA-associated vasculitis, Churg-Strauss syndrome, Wegeners granulomatosus, pemphigus vulgaris, serum sickness, mixed cryoglobulinemia, peripheralneuropathy associated with IgM antibody, microscopic polyangiitis, Hashimoto's thyroiditis,Sjogrens syndrome, a fibrosing condition or primary biliary cirrhosisnon-ANCA vasculitis, psoriasis, asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria, hives, anaphylaxis, bronchitis, chronic obstructive pUlmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, gout, Crohn's disease, mucous colitis, ulcerative colitis, allergy to an intestinal antigen, diabetes or obesity. restenosis, atherosclerosis, stroke, myocardial infarction, ischemic damage Huntington's disease, Alzheimer's disease, or viral or bacterial-associated encephalitis or damage.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式